A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer

Thomas G. Frazier, Kevin R. Fox, J. Stanley Smith, Christine Laronga, Anita McSwain, Devchand Paul, Michael Schultz, Joseph Stilwill, Christine Teal, Tracey Weisberg, Judith F. Vacchino, Amy P. Sing, Dasha Cherepanov, Wendy Hsiao, Eunice Chang, Michael S. Broder

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (>31). This was a multicenter chart review of >18 year old women with pN1mi breast cancer, HER2(-)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0-50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(-)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(-)/ER+ pN1mi breast cancer patients.

Original languageEnglish (US)
Pages (from-to)107-122
Number of pages16
JournalPharmaceuticals
Volume8
Issue number1
DOIs
StatePublished - Mar 7 2015

Fingerprint

Retrospective Studies
Breast Neoplasms
Recurrence
Genes
Therapeutics
Drug Therapy
Segmental Mastectomy
Mastectomy
Osteoarthritis
Type 2 Diabetes Mellitus
Osteoporosis
Histology
Hypertension
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Frazier, T. G., Fox, K. R., Stanley Smith, J., Laronga, C., McSwain, A., Paul, D., ... Broder, M. S. (2015). A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer. Pharmaceuticals, 8(1), 107-122. https://doi.org/10.3390/ph8010107
Frazier, Thomas G. ; Fox, Kevin R. ; Stanley Smith, J. ; Laronga, Christine ; McSwain, Anita ; Paul, Devchand ; Schultz, Michael ; Stilwill, Joseph ; Teal, Christine ; Weisberg, Tracey ; Vacchino, Judith F. ; Sing, Amy P. ; Cherepanov, Dasha ; Hsiao, Wendy ; Chang, Eunice ; Broder, Michael S. / A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer. In: Pharmaceuticals. 2015 ; Vol. 8, No. 1. pp. 107-122.
@article{2dd3b5edad254dd881ed0a2c976e742d,
title = "A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer",
abstract = "To assess clinical utility of the 21-gene assay (Oncotype DX{\circledR} Recurrence Score{\circledR}), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (>31). This was a multicenter chart review of >18 year old women with pN1mi breast cancer, HER2(-)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9{\%} had ECOG performance status 0; 33.7{\%} had hypertension, 22.7{\%} had osteoporosis, 18.8{\%} had osteoarthritis, and 8.8{\%} had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0-50). 48.6{\%} had a mastectomy; 55.8{\%} had a lumpectomy. 19.8{\%} of low-risk group patients were recommended chemotherapy vs. 57.9{\%} in the intermediate-risk group and 100{\%} in the high-risk group (p < 0.001). A total of 80.2{\%} of the low-risk group were recommended endocrine therapy alone, while 77.8{\%} of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(-)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(-)/ER+ pN1mi breast cancer patients.",
author = "Frazier, {Thomas G.} and Fox, {Kevin R.} and {Stanley Smith}, J. and Christine Laronga and Anita McSwain and Devchand Paul and Michael Schultz and Joseph Stilwill and Christine Teal and Tracey Weisberg and Vacchino, {Judith F.} and Sing, {Amy P.} and Dasha Cherepanov and Wendy Hsiao and Eunice Chang and Broder, {Michael S.}",
year = "2015",
month = "3",
day = "7",
doi = "10.3390/ph8010107",
language = "English (US)",
volume = "8",
pages = "107--122",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

Frazier, TG, Fox, KR, Stanley Smith, J, Laronga, C, McSwain, A, Paul, D, Schultz, M, Stilwill, J, Teal, C, Weisberg, T, Vacchino, JF, Sing, AP, Cherepanov, D, Hsiao, W, Chang, E & Broder, MS 2015, 'A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer', Pharmaceuticals, vol. 8, no. 1, pp. 107-122. https://doi.org/10.3390/ph8010107

A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer. / Frazier, Thomas G.; Fox, Kevin R.; Stanley Smith, J.; Laronga, Christine; McSwain, Anita; Paul, Devchand; Schultz, Michael; Stilwill, Joseph; Teal, Christine; Weisberg, Tracey; Vacchino, Judith F.; Sing, Amy P.; Cherepanov, Dasha; Hsiao, Wendy; Chang, Eunice; Broder, Michael S.

In: Pharmaceuticals, Vol. 8, No. 1, 07.03.2015, p. 107-122.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer

AU - Frazier, Thomas G.

AU - Fox, Kevin R.

AU - Stanley Smith, J.

AU - Laronga, Christine

AU - McSwain, Anita

AU - Paul, Devchand

AU - Schultz, Michael

AU - Stilwill, Joseph

AU - Teal, Christine

AU - Weisberg, Tracey

AU - Vacchino, Judith F.

AU - Sing, Amy P.

AU - Cherepanov, Dasha

AU - Hsiao, Wendy

AU - Chang, Eunice

AU - Broder, Michael S.

PY - 2015/3/7

Y1 - 2015/3/7

N2 - To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (>31). This was a multicenter chart review of >18 year old women with pN1mi breast cancer, HER2(-)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0-50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(-)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(-)/ER+ pN1mi breast cancer patients.

AB - To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (>31). This was a multicenter chart review of >18 year old women with pN1mi breast cancer, HER2(-)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0-50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(-)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(-)/ER+ pN1mi breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84930210398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930210398&partnerID=8YFLogxK

U2 - 10.3390/ph8010107

DO - 10.3390/ph8010107

M3 - Comment/debate

AN - SCOPUS:84930210398

VL - 8

SP - 107

EP - 122

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 1

ER -